AbbVie invests $380 million to expand U.S. API manufacturing
Construction is scheduled to begin in spring 2026, with the site expected to be fully operational by 2029.
AbbVie
AbbVie breaks ground on new API facility in North Chicago
AbbVie said the site will be fully operational by 2027, enabling API production for select European and Asian products in the U.S.